Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care (AMBROBiMM)

Assistance Publique - Hôpitaux de Paris

Status: Terminated

Conditions: Multiple Myeloma

Treatments: Biological: Blood and urine collection

Study type: Observational

Funder types: Other; NETWORK

Identifiers

NCT04111809

APH190198

Details and patient eligibility

About

The aim of this study is looking at the Kinetics of bone turnover markers (C-terminal telopeptides of type I collagene (CTX), amino-terminal telopeptide of type 1 collagen (NTX), Dickkopf-1 (DKK-1) and Sclerostin (SOST)) in serum and urine until 12 months in Patients with Multiple Myeloma Treated With intravenous bisphosphonates in routine care.

Enrollment: 3 patients

Sex: All

Ages: 65 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. Patient aged 65 to 75 years of age
2. Patient with symptomatic multiple myeloma as defined by the criteria of the IMWG
3. Need to introduced an antiresorptive bone treatment by intravenous bisphosphonate with bone imaging mapping (PET-scanner preferentially) in routine care
4. Ability and willingness to follow scheduled visits with requested biological samples

Exclusion Criteria

- Patients previously treated with intravenous biphosphonate

Trial design

3 participants in 1 patient group

intravenous biphosphonate

Description:

Patients treated with intravenous bisphosphonate until 12 months in routine care

Treatment:

Biological: Blood and urine collection